Using degraded medication can lead to ineffective treatment or localized skin reactions at the injection site
As an emerging obesity medication, retatrutide has attracted widespread interest due to its unique chemical architecture, which allows it to interface with three distinct metabolic pathways rather than one or two
Several additional percentage points of weight loss translate to significantly greater improvements in metabolic health markers, joint pain, mobility, and quality of life measures
With an elimination half-life of approximately 1 week, semaglutide will be present in the circulation for about 5 weeks after the last dose
It is not approved for mild OSA, for people without obesity, or for central sleep apnea, and it is meant to complement, not replace, standard care